Skip to main content
Top
Published in: Medical Oncology 2/2015

01-02-2015 | Review Article

Survivorship in untreated breast cancer patients

Authors: Carlos M. Galmarini, Olivier Tredan, Felipe C. Galmarini

Published in: Medical Oncology | Issue 2/2015

Login to get access

Abstract

In any disease, the knowledge of the natural history of untreated cases provides a real background against which the real advantages of a new treatment itself are judged. Fortunately, in the present days, there are scant data on outcomes in patients with untreated breast cancer. In an attempt to provide this background against which the virtues of current curative and palliative treatments can be more accurately assessed, we have reviewed the literature regarding published untreated breast cancer series. Taking into consideration all the difficulties of analyzing reports written on the last half of the nineteenth century or on the first half of the twentieth century, in most reports, patients survived almost 3–4 years without any type of treatment. Worth mentioning, approximately 5–10 % of untreated patients lived longer than 10 years. Thus, the spectrum of clinical aggressiveness of untreated breast cancer varies between virulence and chronic disease. These facts should be taken into account when considering the value of current treatments for early-stage disease.
Literature
1.
go back to reference Peto R, Davies C, Godwin J, Gray R, Pan HC, Clarke M, et al. Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomised trials. Lancet. 2012;379(9814):432–44.PubMedCrossRef Peto R, Davies C, Godwin J, Gray R, Pan HC, Clarke M, et al. Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomised trials. Lancet. 2012;379(9814):432–44.PubMedCrossRef
2.
go back to reference Rachet B, Maringe C, Nur U, Quaresma M, Shah A, Woods LM, et al. Population-based cancer survival trends in England and Wales up to 2007: an assessment of the NHS cancer plan for England. Lancet Oncol. 2009;10(4):351–69.PubMedCrossRef Rachet B, Maringe C, Nur U, Quaresma M, Shah A, Woods LM, et al. Population-based cancer survival trends in England and Wales up to 2007: an assessment of the NHS cancer plan for England. Lancet Oncol. 2009;10(4):351–69.PubMedCrossRef
3.
6.
go back to reference Easson EC, Russell MH. The curability of cancer in various sites. London: Pittman Inc; 1968. Easson EC, Russell MH. The curability of cancer in various sites. London: Pittman Inc; 1968.
7.
go back to reference Pocock SJ, Gore SM, Kerr GR. Long term survival analysis: the curability of breast cancer. Stat Med. 1982;1(2):93–104.PubMedCrossRef Pocock SJ, Gore SM, Kerr GR. Long term survival analysis: the curability of breast cancer. Stat Med. 1982;1(2):93–104.PubMedCrossRef
10.
go back to reference Cade S. Modern treatment of carcinoma of the breast. Med Press. 1948;219(20):435–8.PubMed Cade S. Modern treatment of carcinoma of the breast. Med Press. 1948;219(20):435–8.PubMed
11.
go back to reference Bloom HJG. The natural history of untreated breast cancer. Ann N Y Acad Sci. 1964;114(1):747–54. Bloom HJG. The natural history of untreated breast cancer. Ann N Y Acad Sci. 1964;114(1):747–54.
12.
go back to reference Bloom HJG, Richardson WW, Harries EJ. Natural history of untreated breast cancer (1805–1933). Comparison of untreated and treated cases according to histological grade of malignancy. Br Med J. 1962;2(5299):213–21.PubMedCentralPubMedCrossRef Bloom HJG, Richardson WW, Harries EJ. Natural history of untreated breast cancer (1805–1933). Comparison of untreated and treated cases according to histological grade of malignancy. Br Med J. 1962;2(5299):213–21.PubMedCentralPubMedCrossRef
14.
go back to reference Gross SW. A practical treatise of tumours of the mammary gland. New York: Appelton & Co; 1880. Gross SW. A practical treatise of tumours of the mammary gland. New York: Appelton & Co; 1880.
16.
go back to reference Greenwood M. A report on the natural duration of cancer: reports on public health andmedical subjects. London: H.M.S.O; 1926. Greenwood M. A report on the natural duration of cancer: reports on public health andmedical subjects. London: H.M.S.O; 1926.
17.
go back to reference Daland EM. Untreated carcinoma of the breast. Surg Gynecol Obstet. 1927;44(1):264–8. Daland EM. Untreated carcinoma of the breast. Surg Gynecol Obstet. 1927;44(1):264–8.
18.
go back to reference Forber JE. Report of public health medical subjects. London: H.M.S.O; 1931 1931. Forber JE. Report of public health medical subjects. London: H.M.S.O; 1931 1931.
19.
go back to reference MacKay EN, Sellers AH. Breast cancer at the Ontario Cancer Clinics, 1938–1956. A statistical review. Ontario: Medical statistics branch, Ontario department of health; 1965. MacKay EN, Sellers AH. Breast cancer at the Ontario Cancer Clinics, 1938–1956. A statistical review. Ontario: Medical statistics branch, Ontario department of health; 1965.
21.
go back to reference Gross SW, Boenning HC. Some points in the life and diagnosis of carcinoma of the mammary gland, based upon a study of one hundred cases. Boston Med Surg J. 1880;102(1):289–93.CrossRef Gross SW, Boenning HC. Some points in the life and diagnosis of carcinoma of the mammary gland, based upon a study of one hundred cases. Boston Med Surg J. 1880;102(1):289–93.CrossRef
22.
go back to reference Nathanson IT, Welch CE. Life expectancy and incidence of malignant disease: carcinoma of the breast. Am J Cancer. 1936;28(1):40–53. Nathanson IT, Welch CE. Life expectancy and incidence of malignant disease: carcinoma of the breast. Am J Cancer. 1936;28(1):40–53.
24.
go back to reference Baum M, Demicheli R, Hrushesky W, Retsky M. Does surgery unfavourably perturb the “natural history” of early breast cancer by accelerating the appearance of distant metastases? Eur J Cancer. 2005;41(4):508–15.PubMedCrossRef Baum M, Demicheli R, Hrushesky W, Retsky M. Does surgery unfavourably perturb the “natural history” of early breast cancer by accelerating the appearance of distant metastases? Eur J Cancer. 2005;41(4):508–15.PubMedCrossRef
25.
go back to reference Johnstone PA, Norton MS, Riffenburgh RH. Survival of patients with untreated breast cancer. J Surg Oncol. 2000;73(4):273–7.PubMedCrossRef Johnstone PA, Norton MS, Riffenburgh RH. Survival of patients with untreated breast cancer. J Surg Oncol. 2000;73(4):273–7.PubMedCrossRef
26.
go back to reference Verkooijen HM, Fioretta GM, Rapiti E, Bonnefoi H, Vlastos G, Kurtz J, et al. Patients’ refusal of surgery strongly impairs breast cancer survival. Ann Surg. 2005;242(2):276–80.PubMedCentralPubMedCrossRef Verkooijen HM, Fioretta GM, Rapiti E, Bonnefoi H, Vlastos G, Kurtz J, et al. Patients’ refusal of surgery strongly impairs breast cancer survival. Ann Surg. 2005;242(2):276–80.PubMedCentralPubMedCrossRef
27.
go back to reference Chang EY, Glissmeyer M, Tonnes S, Hudson T, Johnson N. Outcomes of breast cancer in patients who use alternative therapies as primary treatment. Am J Surg. 2006;192(4):471–3.PubMedCrossRef Chang EY, Glissmeyer M, Tonnes S, Hudson T, Johnson N. Outcomes of breast cancer in patients who use alternative therapies as primary treatment. Am J Surg. 2006;192(4):471–3.PubMedCrossRef
28.
go back to reference Han E, Johnson N, DelaMelena T, Glissmeyer M, Steinbock K. Alternative therapy used as primary treatment for breast cancer negatively impacts outcomes. Ann Surg Oncol. 2011;18(4):912–6.PubMedCrossRef Han E, Johnson N, DelaMelena T, Glissmeyer M, Steinbock K. Alternative therapy used as primary treatment for breast cancer negatively impacts outcomes. Ann Surg Oncol. 2011;18(4):912–6.PubMedCrossRef
29.
go back to reference Joseph K, Vrouwe S, Kamruzzaman A, Balbaid A, Fenton D, Berendt R, et al. Outcome analysis of breast cancer patients who declined evidence-based treatment. World J Surg Oncol. 2012;10(1):118.PubMedCentralPubMedCrossRef Joseph K, Vrouwe S, Kamruzzaman A, Balbaid A, Fenton D, Berendt R, et al. Outcome analysis of breast cancer patients who declined evidence-based treatment. World J Surg Oncol. 2012;10(1):118.PubMedCentralPubMedCrossRef
30.
go back to reference Demicheli R, Retsky MW, Hrushesky WJ, Baum M. Tumor dormancy and surgery-driven interruption of dormancy in breast cancer: learning from failures. Nat Clin Pract Oncol. 2007;4(12):699–710.PubMedCrossRef Demicheli R, Retsky MW, Hrushesky WJ, Baum M. Tumor dormancy and surgery-driven interruption of dormancy in breast cancer: learning from failures. Nat Clin Pract Oncol. 2007;4(12):699–710.PubMedCrossRef
31.
go back to reference Demicheli R, Valagussa P, Bonadonna G. Double-peaked time distribution of mortality for breast cancer patients undergoing mastectomy. Breast Cancer Res Treat. 2002;75(2):127–34.PubMedCrossRef Demicheli R, Valagussa P, Bonadonna G. Double-peaked time distribution of mortality for breast cancer patients undergoing mastectomy. Breast Cancer Res Treat. 2002;75(2):127–34.PubMedCrossRef
32.
go back to reference Galmarini CM, Tredan O, Galmarini FC. Concomitant resistance and early-breast cancer: should we change treatment strategies? Cancer Metastasis Rev. 2014;33(1):271–83.PubMedCrossRef Galmarini CM, Tredan O, Galmarini FC. Concomitant resistance and early-breast cancer: should we change treatment strategies? Cancer Metastasis Rev. 2014;33(1):271–83.PubMedCrossRef
33.
go back to reference Ambs S. Prognostic significance of subtype classification for short- and long-term survival in breast cancer: survival time holds the key. PLoS Med. 2010;7(5):e1000281.PubMedCentralPubMedCrossRef Ambs S. Prognostic significance of subtype classification for short- and long-term survival in breast cancer: survival time holds the key. PLoS Med. 2010;7(5):e1000281.PubMedCentralPubMedCrossRef
34.
go back to reference Karrison TG, Ferguson DJ, Meier P. Dormancy of mammary carcinoma after mastectomy. J Natl Cancer Inst. 1999;91(1):80–5.PubMedCrossRef Karrison TG, Ferguson DJ, Meier P. Dormancy of mammary carcinoma after mastectomy. J Natl Cancer Inst. 1999;91(1):80–5.PubMedCrossRef
35.
go back to reference Jerez JM, Franco L, Alba E, Llombart-Cussac A, Lluch A, Ribelles N, et al. Improvement of breast cancer relapse prediction in high risk intervals using artificial neural networks. Breast Cancer Res Treat. 2005;94(3):265–72.PubMedCrossRef Jerez JM, Franco L, Alba E, Llombart-Cussac A, Lluch A, Ribelles N, et al. Improvement of breast cancer relapse prediction in high risk intervals using artificial neural networks. Breast Cancer Res Treat. 2005;94(3):265–72.PubMedCrossRef
36.
go back to reference Sant M, Gatta G, Micheli A, Verdecchia A, Capocaccia R, Crosignani P, et al. Survival and age at diagnosis of breast cancer in a population-based cancer registry. Eur J Cancer. 1991;27(8):981–4.PubMedCrossRef Sant M, Gatta G, Micheli A, Verdecchia A, Capocaccia R, Crosignani P, et al. Survival and age at diagnosis of breast cancer in a population-based cancer registry. Eur J Cancer. 1991;27(8):981–4.PubMedCrossRef
37.
go back to reference Baum M, Badwe RA. Does surgery influence the natural history of breast cancer? In: Wise H, Johnson HJ, editors. Breast cancer: controversies in management. Armonk, NY: Futura; 1994. p. 61–9. Baum M, Badwe RA. Does surgery influence the natural history of breast cancer? In: Wise H, Johnson HJ, editors. Breast cancer: controversies in management. Armonk, NY: Futura; 1994. p. 61–9.
38.
go back to reference Yakovlev AY, Tsodikov AD, Boucher K, Kerber R. The shape of the hazard function in breast carcinoma: curability of the disease revisited. Cancer. 1999;85(8):1789–98.PubMedCrossRef Yakovlev AY, Tsodikov AD, Boucher K, Kerber R. The shape of the hazard function in breast carcinoma: curability of the disease revisited. Cancer. 1999;85(8):1789–98.PubMedCrossRef
39.
go back to reference Gao F, Tan SB, Machin D, Wong NS. Confirmation of double-peaked time distribution of mortality among Asian breast cancer patients in a population-based study. Breast Cancer Res. 2007;9(2):R21.PubMedCentralPubMedCrossRef Gao F, Tan SB, Machin D, Wong NS. Confirmation of double-peaked time distribution of mortality among Asian breast cancer patients in a population-based study. Breast Cancer Res. 2007;9(2):R21.PubMedCentralPubMedCrossRef
40.
go back to reference Mc KN. Control of cancer mortality. Lancet. 1954;266(6805):251–4. Mc KN. Control of cancer mortality. Lancet. 1954;266(6805):251–4.
42.
go back to reference Vorherr H. Pathobiology of breast cancer: hypothesis of biological predetermination and long-term survival. Klin Wochenschr. 1981;59(15):819–29.PubMedCrossRef Vorherr H. Pathobiology of breast cancer: hypothesis of biological predetermination and long-term survival. Klin Wochenschr. 1981;59(15):819–29.PubMedCrossRef
43.
go back to reference Ruggiero RA, Bruzzo J, Chiarella P, Bustuoabad OD, Meiss RP, Pasqualini CD. Concomitant tumor resistance: the role of tyrosine isomers in the mechanisms of metastases control. Cancer Res. 2012;72(5):1043–50.PubMedCrossRef Ruggiero RA, Bruzzo J, Chiarella P, Bustuoabad OD, Meiss RP, Pasqualini CD. Concomitant tumor resistance: the role of tyrosine isomers in the mechanisms of metastases control. Cancer Res. 2012;72(5):1043–50.PubMedCrossRef
44.
go back to reference Galmarini D, Galmarini CM, Galmarini FC. Cancer chemotherapy: a critical analysis of its 60 years of history. Crit Rev Oncol Hematol. 2012;84(2):181–99.PubMedCrossRef Galmarini D, Galmarini CM, Galmarini FC. Cancer chemotherapy: a critical analysis of its 60 years of history. Crit Rev Oncol Hematol. 2012;84(2):181–99.PubMedCrossRef
45.
go back to reference Retsky M, Demicheli R, Hrushesky WJ. Does surgery induce angiogenesis in breast cancer? Indirect evidence from relapse pattern and mammography paradox. Int J Surg. 2005;3(3):179–87.PubMedCrossRef Retsky M, Demicheli R, Hrushesky WJ. Does surgery induce angiogenesis in breast cancer? Indirect evidence from relapse pattern and mammography paradox. Int J Surg. 2005;3(3):179–87.PubMedCrossRef
46.
go back to reference Retsky M, Rogers R, Demicheli R, Hrushesky WJ, Gukas I, Vaidya JS, et al. NSAID analgesic ketorolac used perioperatively may suppress early breast cancer relapse: particular relevance to triple negative subgroup. Breast Cancer Res Treat. 2012;134(2):881–8.PubMedCrossRef Retsky M, Rogers R, Demicheli R, Hrushesky WJ, Gukas I, Vaidya JS, et al. NSAID analgesic ketorolac used perioperatively may suppress early breast cancer relapse: particular relevance to triple negative subgroup. Breast Cancer Res Treat. 2012;134(2):881–8.PubMedCrossRef
47.
go back to reference Adair F, Berg J, Joubert L, Robbins GF. Long-term followup of breast cancer patients: the 30-year report. Cancer. 1974;33(4):1145–50.PubMedCrossRef Adair F, Berg J, Joubert L, Robbins GF. Long-term followup of breast cancer patients: the 30-year report. Cancer. 1974;33(4):1145–50.PubMedCrossRef
48.
go back to reference Campos JL. Observations on the mortality from carcinoma of the breast. Br J Radiol. 1972;45(529):31–8.PubMedCrossRef Campos JL. Observations on the mortality from carcinoma of the breast. Br J Radiol. 1972;45(529):31–8.PubMedCrossRef
49.
go back to reference Greenberg PA, Hortobagyi GN, Smith TL, Ziegler LD, Frye DK, Buzdar AU. Long-term follow-up of patients with complete remission following combination chemotherapy for metastatic breast cancer. J Clin Oncol. 1996;14(8):2197–205.PubMed Greenberg PA, Hortobagyi GN, Smith TL, Ziegler LD, Frye DK, Buzdar AU. Long-term follow-up of patients with complete remission following combination chemotherapy for metastatic breast cancer. J Clin Oncol. 1996;14(8):2197–205.PubMed
50.
go back to reference Brinkley D, Haybittle JL. A 15-year follow-up study of patients treated for carcinoma of the breast. Br J Radiol. 1968;41(483):215–21.PubMedCrossRef Brinkley D, Haybittle JL. A 15-year follow-up study of patients treated for carcinoma of the breast. Br J Radiol. 1968;41(483):215–21.PubMedCrossRef
51.
go back to reference Brinkley D, Haybittle JL. Long-term survival of women with breast cancer. Lancet. 1984;1(8386):1118.PubMedCrossRef Brinkley D, Haybittle JL. Long-term survival of women with breast cancer. Lancet. 1984;1(8386):1118.PubMedCrossRef
53.
go back to reference Guth U, Huang DJ, Dirnhofer S, Rochlitz C, Wight E. Distant metastatic breast cancer as an incurable disease: a tenet with a need for revision. Cancer J. 2009;15(1):81–6.PubMedCrossRef Guth U, Huang DJ, Dirnhofer S, Rochlitz C, Wight E. Distant metastatic breast cancer as an incurable disease: a tenet with a need for revision. Cancer J. 2009;15(1):81–6.PubMedCrossRef
54.
go back to reference Blows FM, Driver KE, Schmidt MK, Broeks A, van Leeuwen FE, Wesseling J, et al. Subtyping of breast cancer by immunohistochemistry to investigate a relationship between subtype and short and long term survival: a collaborative analysis of data for 10,159 cases from 12 studies. PLoS Med. 2010;7(5):e1000279.PubMedCentralPubMedCrossRef Blows FM, Driver KE, Schmidt MK, Broeks A, van Leeuwen FE, Wesseling J, et al. Subtyping of breast cancer by immunohistochemistry to investigate a relationship between subtype and short and long term survival: a collaborative analysis of data for 10,159 cases from 12 studies. PLoS Med. 2010;7(5):e1000279.PubMedCentralPubMedCrossRef
55.
go back to reference Yardley DA, Tripathy D, Brufsky AM, Rugo HS, Kaufman PA, Mayer M, et al. Long-term survivor characteristics in HER2-positive metastatic breast cancer from registHER. Br J Cancer. 2014;110(11):2756–64.PubMedCentralPubMedCrossRef Yardley DA, Tripathy D, Brufsky AM, Rugo HS, Kaufman PA, Mayer M, et al. Long-term survivor characteristics in HER2-positive metastatic breast cancer from registHER. Br J Cancer. 2014;110(11):2756–64.PubMedCentralPubMedCrossRef
56.
go back to reference Koch L, Jansen L, Herrmann A, Stegmaier C, Holleczek B, Singer S, et al. Quality of life in long-term breast cancer survivors—a 10-year longitudinal population-based study. Acta Oncol. 2013;52(6):1119–28.PubMedCrossRef Koch L, Jansen L, Herrmann A, Stegmaier C, Holleczek B, Singer S, et al. Quality of life in long-term breast cancer survivors—a 10-year longitudinal population-based study. Acta Oncol. 2013;52(6):1119–28.PubMedCrossRef
57.
go back to reference Ali HR, Provenzano E, Dawson SJ, Blows FM, Liu B, Shah M, et al. Association between CD8+ T-cell infiltration and breast cancer survival in 12,439 patients. Ann Oncol. 2014;25(8):1536–43.PubMedCrossRef Ali HR, Provenzano E, Dawson SJ, Blows FM, Liu B, Shah M, et al. Association between CD8+ T-cell infiltration and breast cancer survival in 12,439 patients. Ann Oncol. 2014;25(8):1536–43.PubMedCrossRef
58.
go back to reference Jordan VC, Ford LG. Paradoxical clinical effect of estrogen on breast cancer risk: a “new” biology of estrogen-induced apoptosis. Cancer Prev Res (Phila). 2011;4(5):633–7.CrossRef Jordan VC, Ford LG. Paradoxical clinical effect of estrogen on breast cancer risk: a “new” biology of estrogen-induced apoptosis. Cancer Prev Res (Phila). 2011;4(5):633–7.CrossRef
59.
go back to reference LaCroix AZ, Chlebowski RT, Manson JE, Aragaki AK, Johnson KC, Martin L, et al. Health outcomes after stopping conjugated equine estrogens among postmenopausal women with prior hysterectomy: a randomized controlled trial. JAMA. 2011;305(13):1305–14.PubMedCentralPubMedCrossRef LaCroix AZ, Chlebowski RT, Manson JE, Aragaki AK, Johnson KC, Martin L, et al. Health outcomes after stopping conjugated equine estrogens among postmenopausal women with prior hysterectomy: a randomized controlled trial. JAMA. 2011;305(13):1305–14.PubMedCentralPubMedCrossRef
60.
go back to reference Demicheli R, Abbattista A, Miceli R, Valagussa P, Bonadonna G. Time distribution of the recurrence risk for breast cancer patients undergoing mastectomy: further support about the concept of tumor dormancy. Breast Cancer Res Treat. 1996;41(2):177–85.PubMedCrossRef Demicheli R, Abbattista A, Miceli R, Valagussa P, Bonadonna G. Time distribution of the recurrence risk for breast cancer patients undergoing mastectomy: further support about the concept of tumor dormancy. Breast Cancer Res Treat. 1996;41(2):177–85.PubMedCrossRef
61.
go back to reference Demicheli R, Miceli R, Moliterni A, Zambetti M, Hrushesky WJ, Retsky MW, et al. Breast cancer recurrence dynamics following adjuvant CMF is consistent with tumor dormancy and mastectomy-driven acceleration of the metastatic process. Ann Oncol. 2005;16(9):1449–57.PubMedCrossRef Demicheli R, Miceli R, Moliterni A, Zambetti M, Hrushesky WJ, Retsky MW, et al. Breast cancer recurrence dynamics following adjuvant CMF is consistent with tumor dormancy and mastectomy-driven acceleration of the metastatic process. Ann Oncol. 2005;16(9):1449–57.PubMedCrossRef
62.
Metadata
Title
Survivorship in untreated breast cancer patients
Authors
Carlos M. Galmarini
Olivier Tredan
Felipe C. Galmarini
Publication date
01-02-2015
Publisher
Springer US
Published in
Medical Oncology / Issue 2/2015
Print ISSN: 1357-0560
Electronic ISSN: 1559-131X
DOI
https://doi.org/10.1007/s12032-014-0466-x

Other articles of this Issue 2/2015

Medical Oncology 2/2015 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.